151 related articles for article (PubMed ID: 53342)
1. Letter: Oral hypoglycaemics in diabetes mellitus.
Keen H; Jarrett RJ; Fuller JH
Lancet; 1975 Nov; 2(7940):865. PubMed ID: 53342
[No Abstract] [Full Text] [Related]
2. Oral hypoglycaemics in diabetes mellitus.
Lancet; 1975 Sep; 2(7933):489-91. PubMed ID: 51292
[No Abstract] [Full Text] [Related]
3. Editorial: Oral hypoglycemic drugs.
Scoville AB
J Tenn Med Assoc; 1975 Apr; 68(4):319-20. PubMed ID: 1117723
[No Abstract] [Full Text] [Related]
4. The influence of diagnostic criteria on the mortality findings in the University Group Diabetic Programme study of diabetic therapy.
Gray RH
Med J Aust; 1973 Mar; 1(12):594-6. PubMed ID: 4573383
[No Abstract] [Full Text] [Related]
5. [Oral therapy in diabetes].
Kirkeby K
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1620-1. PubMed ID: 4588817
[No Abstract] [Full Text] [Related]
6. Farewell to phenformin for treating diabetes mellitus.
Williams RH; Palmer JP
Ann Intern Med; 1975 Oct; 83(4):567-8. PubMed ID: 1166991
[No Abstract] [Full Text] [Related]
7. [The venture of University Group Diabetes Program (UGDP). Some personal reflexions. Tolbutamide and phenformin under accusation].
Pirart J
Nouv Presse Med; 1972 Jan; 1(5):325-8. PubMed ID: 5010448
[No Abstract] [Full Text] [Related]
8. Antidiabetic agents and vascular events.
Keen H
J Clin Pathol Suppl (R Coll Pathol); 1975; 9():99-105. PubMed ID: 783218
[No Abstract] [Full Text] [Related]
9. [Should the prescription of oral antidiabetic drugs be more limited? Results from controlled clinical trials].
Folling I
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1604-6. PubMed ID: 4769481
[No Abstract] [Full Text] [Related]
10. [Heart death and oral antidiabetics; the last judgement].
Touber JL
Ned Tijdschr Geneeskd; 1975 Sep; 119(39):1506-8. PubMed ID: 1101083
[No Abstract] [Full Text] [Related]
11. Management of adult-onset diabetes. The impact of the University Group Diabetes Program.
Goetz FC
Postgrad Med; 1972 Jul; 52(1):63-8. PubMed ID: 5067890
[No Abstract] [Full Text] [Related]
12. Comments on the UGDP study.
Schöffling K
Horm Metab Res; 1974; Suppl 4():188-91. PubMed ID: 4608018
[No Abstract] [Full Text] [Related]
13. [Increased risk of cardiovascular complications with oral hypoglycemic agents?].
Mueller R
Acta Diabetol Lat; 1970; 7(5):805-23. PubMed ID: 4949515
[No Abstract] [Full Text] [Related]
14. The UGDP--tolbutamide and mortality.
Knowles HC
Horm Metab Res; 1974; Suppl 4():186-8. PubMed ID: 4609432
[No Abstract] [Full Text] [Related]
15. Audit confirms conclusions of UGDP study on oral diabetes drugs.
FDA Drug Bull; 1978 Dec-1979 Jan; 8(6):34-6. PubMed ID: 720789
[No Abstract] [Full Text] [Related]
16. The tolbutamide controversy.
Compr Ther; 1975 May; 1(1):19-20. PubMed ID: 1222531
[No Abstract] [Full Text] [Related]
17. Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents.
JAMA; 1975 Feb; 231(6):583-608. PubMed ID: 1089822
[No Abstract] [Full Text] [Related]
18. [Clinico-statistical studies of the use of oral hypoglycemic agents in the therapy of diabetes: critical evaluation of their effectiveness and tolerance].
Torri A; Zanni A; Roncaia R; Di Saverio S
Clin Ter; 1977 Jul; 82(1):45-56. PubMed ID: 409583
[No Abstract] [Full Text] [Related]
19. The FDA and hypoglycemic drugs.
Davidson JK
JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764
[No Abstract] [Full Text] [Related]
20. [Clinical testing of Tolbutaphen in the treatment of adult diabetes].
Schneider J; Kaffarnik H
Z Allgemeinmed; 1975 Jan; 51(2):74-5. PubMed ID: 766424
[No Abstract] [Full Text] [Related]
[Next] [New Search]